Accele Biopharma

David Green, the founder of Hobby Lobby, established Accele Biopharma and maintains oversight alongside his son Steve Green, who serves on the investment committee. The firm recruits scientific and clinical advisory expertise for deal-level diligence, but ultimate capital-allocation authority rests with the Green family principals.

The capital originates from Hobby Lobby, the privately held arts-and-crafts retailer David Green founded in 1972. The company reports revenues exceeding $7 billion annually and has been operated debt-free throughout its history, generating consistent cash flow that funds the family's investment activities including Accele Biopharma.

Accele Biopharma functions as a dedicated healthcare-investment arm within the Green family's single family office. It does not accept outside limited partners, charges no management fees to third parties, and can hold portfolio positions indefinitely — a permanent-capital structure that distinguishes it from institutional venture funds.

Accele Biopharma invests directly into therapeutics companies and participates in syndicated rounds alongside other family offices and specialist healthcare funds. There is no public record of the firm making blind-pool fund commitments as a limited partner; its known posture favors direct co-investment where it can evaluate individual assets.

The firm targets seed-through clinical-stage therapeutics, with an emphasis on regulatory-stage assets and platform companies. It is known to support portfolio companies across the full FDA-approval cycle, consistent with a permanent-capital mandate that does not require near-term liquidity.